-
Product Insights
Clinical Trials in 2024 – A Preview of Trials Planned to Initiate and Estimated to Complete
This report provides a preview of clinical trials that are planned to be initiated and projected to be completed in 2024.
-
Product Insights
NewClinical Trials Scorecard for Investigations in 2023
This report provides an overview of global clinical trials with a start date between January 1, 2023, and December 31, 2023.
-
Company Insights
NewPhonePe – Competitor Profile
PhonePe is one of the most widely adopted mobile wallets in India, with over 520 million users. The company was founded as a fintech startup in late 2015; by April 2016, PhonePe was operating as a subsidiary of ecommerce platform Flipkart. With heavy financial backing from Flipkart, the mobile wallet service flourished. In 2020, US retail giant Walmart (the owner of Flipkart) decided to spin off PhonePe to operate as a separate entity (a process that was completed in December...
-
Product Insights
NewLikelihood of Approval Analysis for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Overview How likely is it that the drugs in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. End-Stage Kidney Disease (End-Stage Renal Disease...
-
Company Insights
NewWorldline – Competitor Profile
Worldline Group is one of the world’s leading payment and transactional service providers, offering end-to-end solutions covering the entire payment value chain. It has omnichannel solutions for merchants, banks, acquirers, payment services providers (PSPs), businesses, and governments. Worldline operates its services in 170 countries, supporting payments in 140 currencies. Worldline operates through three segments—Merchant Services, Financial Services, and Mobility & e-Transactional Services—offering acquiring and processing, card issuing processing, clearing and settlement, open banking, and mobile banking services. Previously, it had...
-
Product Insights
NewLikelihood of Approval Analysis for Alopecia
Overview How likely is it that the drugs in Alopecia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alopecia Overview Alopecia is the partial or complete loss of hair, especially on...
-
Company Insights
NewFiserv – Competitor Profile
Fiserv is a leading global provider of payments and financial services. It provides a wide range of services, including electronic payment processing for electronic bill payments; account-to-account transfers; debit and credit card processing and services; internet and mobile banking systems; card and print personalization services; loan origination and servicing products; as well as fraud and risk management services. Launched in 1984, the company offers its services to over 10,000 financial institution clients in over 100 countries. The company mostly offers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onureg in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Diffuse Large B-Cell Lymphoma Drug Details: Azacitidine (Onureg)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Onureg in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Hairy Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Hairy Cell Leukemia Drug Details: Azacitidine (Onureg) is a...